NEW YORK (GenomeWeb News) – Cepheid's revenues grew 21 percent year over year during the second quarter, the Sunnyvale, Calif.-based firm reported after the close of the market on Thursday.

For the three months ended June 30, total revenues came in at $81.0 million, compared to $67.0 million a year ago. Wall Street analysts had expected revenues of $82.7 million.

Pacing revenue growth was reagent and disposable sales growth to $63.9 million from $49.5 million a year ago, a 29 percent increase. System sales increased 3 percent to $14.5 million from $14.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.